Pfizer has acquired CRISPR Therapeutics for an undisclosed amount, bringing a leader in gene editing technology and its groundbreaking therapies into the multinational pharmaceutical corporation's portfolio. CRISPR Therapeutics has evolved from a research-stage company into a pioneer, notably achieving the historic approval of CASGEVY® (exagamglogene autotemcel), the first-ever CRISPR-based therapy for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia, beginning in late 2023.
CRISPR Therapeutics' core expertise lies in advancing gene editing programs using the Nobel Prize-winning CRISPR technology. The company has developed a diverse portfolio of product candidates targeting a broad range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. Its work has positioned CRISPR technology as a clinically validated approach with the potential to create a new class of transformative medicines.
This acquisition strategically strengthens Pfizer's position in advanced genetic medicines. By integrating CRISPR Therapeutics' validated platform and pipeline, Pfizer gains immediate access to a revolutionary therapeutic modality and an approved product in a critical area of unmet medical need. The move is expected to accelerate Pfizer's research and development efforts in gene-edited therapies, leveraging CRISPR Therapeutics' scientific innovation with Pfizer's extensive global resources and commercial capabilities.
The combined entity aims to expedite the development and delivery of potentially transformative gene-edited medicines to a wider patient population. The integration is anticipated to foster synergies in clinical development, manufacturing, and market access, enabling the expanded application of CRISPR technology across a broader spectrum of severe diseases. This union is poised to enhance the pace at which cutting-edge genetic treatments reach patients worldwide.